# Toxic Shock Syndrome

Toxic shock syndrome is a rapidly progressive toxin-mediated shock syndrome from Staphylococcus aureus or group A Streptococcus. Treat suspected disease before surveillance criteria are complete: resuscitate, obtain cultures, remove or debride the source, and provide pathogen-directed antitoxin therapy.

**Clinical question:** How should clinicians recognize and immediately manage suspected staphylococcal or streptococcal toxic shock syndrome?

Updated: 2026-08-20T23:48:21.660122Z

## What matters in practice
- Suspect TSS in rapidly evolving shock with gastrointestinal symptoms, diffuse erythema or mucosal hyperemia, and organ dysfunction—even when rash is absent or a source is clinically subtle. [11][18]
- For suspected streptococcal toxic shock syndrome (STSS), hospitalization, shock resuscitation, urgent source control, and penicillin plus clindamycin are CDC-supported first-line management. [16]
- Do not delay surgical evaluation when pain is severe or soft-tissue findings progress; deep infection may require debridement, and STSS mortality can exceed 30% despite aggressive care. [16][17]
- IVIG may be considered early for severely ill STSS, but efficacy remains unproven; it is an adjunct, never a substitute for resuscitation, antibiotics, and source control. [16]

## Recognize TSS before surveillance criteria are complete

TSS is a clinical emergency, not a diagnosis to defer pending desquamation or microbiologic confirmation.

TSS results from toxin-producing Staphylococcus aureus or Streptococcus pyogenes. Superantigen activity causes broad T-cell activation and cytokine release, producing capillary leak, hypotension, and multiorgan dysfunction. [19][24] STSS is defined by GAS infection with abrupt shock and organ failure; hypotension generally develops within 24 to 48 hours after initial symptoms. [16]

A diffuse rash is helpful but not required for early action. In a pediatric series, 48% of STSS cases lacked rash; delayed use of clindamycin and IVIG was associated with longer hospitalization among children without rash. [18] TSS may arise from a small or occult focus, and blood cultures can be negative in staphylococcal disease. [11]

STSS should be especially considered with severe focal pain out of proportion to examination, recent surgery or skin disruption, varicella-associated skin lesions, diabetes, alcohol use disorder, or age 65 years or older. NSAID exposure may increase risk, although evidence is limited. [16]
- Clinical triggers for immediate escalation: rapidly progressive hypotension; fever or hypothermia; vomiting or diarrhea; myalgias; altered mental status; diffuse erythema or mucosal hyperemia; thrombocytopenia, coagulopathy, kidney injury, liver injury, hypoxemia, or rapidly expanding soft-tissue abnormalities. [16][18][24]
- Actively inspect for a retained tampon, vaginal device, nasal packing, postoperative wound, abscess, cellulitis, burn, deep soft-tissue infection, or necrotizing infection. [11][24]

*High-yield distinctions between streptococcal and staphylococcal toxic shock syndromes. [16][18][24]*

| Feature | STSS | Staphylococcal TSS |
| --- | --- | --- |
| Usual microbiology | Group A Streptococcus infection with hypotension, multiorgan involvement, and isolation of GAS required for the CSTE case definition. [16] | Toxin-producing Staphylococcus aureus; often associated with localized mucosal, wound, or skin infection. [18][24] |
| Clinical source pattern | Often invasive deep-tissue or bloodstream disease; necrotizing fasciitis or myositis may be present. [16][17] | May arise from menstrual or nonmenstrual localized sources, including wounds, burns, retained foreign material, or packing. [11][24] |
| Rash | May be absent; do not use its absence to lower urgency. [18] | Diffuse erythroderma and later desquamation are characteristic but may not be present initially. [24] |
| Prognosis | CDC states mortality can exceed 30% despite aggressive treatment. [16] | Mortality varies by syndrome and setting; prompt recognition, source control, and supportive care remain essential. [11][24] |

## Order cultures and organ-injury testing while resuscitation proceeds

The diagnostic task is to establish a toxin-mediated syndrome, identify the organism and source, and exclude competing causes of shock.

There is no single diagnostic test for TSS. Obtain blood cultures and cultures from any suspected source before antimicrobials when this does not delay treatment. Evaluate organ involvement with CBC and platelets, comprehensive metabolic panel, creatine kinase, coagulation studies, urinalysis, and assessment for pulmonary involvement. [16][24]

For STSS surveillance classification, the CSTE case definition requires hypotension, multiorgan involvement, and GAS isolation; isolation from a sterile site supports a confirmed case. [16] These criteria optimize specificity and should not be treated as bedside prerequisites for empiric therapy. [18]

Early imaging should be directed by the suspected source and must not postpone exploration when necrotizing soft-tissue infection is plausible. In STSS, severe pain can precede prominent local findings, and bullae or violaceous progression should prompt emergent surgical exploration. [17]
- Obtain immediately: blood cultures; culture or Gram stain of wound, deep tissue, vaginal/cervical, or other implicated source; CBC with differential and platelets; serum creatinine, hepatic tests, bilirubin, electrolytes, CK, lactate, and coagulation studies. [16][24]
- Assess for occult organ dysfunction: urinalysis, chest imaging or oxygenation assessment when respiratory involvement is suspected, and serial evaluation for kidney injury, coagulopathy, hepatic injury, and tissue necrosis. [18]
- Maintain a broad differential for shock with rash or multisystem disease, including bacterial sepsis, necrotizing soft-tissue infection, rickettsial illness, leptospirosis, measles, Kawasaki disease with shock, and drug reactions. [18][24]

*Bedside actions linked to diagnostic findings in suspected TSS. [16][17][18][24]*

| Finding | Interpretation | Immediate action |
| --- | --- | --- |
| Hypotension with suspected GAS infection and at least two organ-system abnormalities | Meets the clinical severity framework for STSS; sterile-site GAS establishes confirmed surveillance classification. [16][17] | Treat as STSS: resuscitate, start penicillin plus clindamycin when GAS is established or strongly suspected, and seek source control. [16] |
| Severe focal pain, rapidly progressive edema/erythema, vesicles, bullae, or violaceous skin | Suggests deep soft-tissue infection or necrotizing fasciitis; examination may initially underestimate disease extent. [17] | Obtain immediate surgical consultation and explore/debride as indicated; do not await late skin findings. [16][17] |
| Diffuse pulmonary infiltrates, pyuria, or coagulation abnormalities | May occur in TSS even when not uniformly represented in case definitions. [18] | Document organ involvement, intensify monitoring and organ support, and continue source-directed evaluation. [18] |
| No rash or negative blood cultures | Does not exclude TSS, particularly early disease or staphylococcal TSS from a localized source. [11][18] | Continue syndrome-based treatment and aggressively search for a source. [11][24] |

## Resuscitate, control the source, and start antitoxin-active therapy

Early ICU-level care is appropriate when shock or evolving organ failure is present.

Hospitalize patients with suspected STSS. Begin standard shock management with intravenous fluid resuscitation and organ support; add vasopressors when hypotension persists despite fluids. [16][24] Serially reassess hemodynamics, urine output, respiratory failure, renal function, hepatic injury, coagulation abnormalities, and evolving skin or soft-tissue findings. [16][24]

Source control is time-critical. Remove tampons, packing, or other retained foreign material; drain abscesses; and obtain urgent surgical assessment for suspected deep infection. CDC specifically notes that surgical debridement may be necessary in STSS. [16]

For confirmed or strongly suspected STSS, CDC identifies penicillin plus clindamycin as first-line antibiotics. [16] Clindamycin is used in combination, not alone, because it suppresses toxin production but is bacteriostatic. [24] The supplied sources do not provide a U.S. dosing regimen for penicillin or clindamycin; use current institutional severe invasive GAS pathways and adjust to kidney function, allergy history, and microbiology results.
- At presentation, use empiric therapy broad enough for MRSA, GAS, and potential polymicrobial soft-tissue infection when the organism and source are uncertain; narrow once cultures and source evaluation clarify the syndrome. [24]
- When GAS is identified, transition to penicillin plus clindamycin unless patient-specific contraindications require an alternative. [16]
- Do not treat antibiotics as a substitute for debridement or removal of an infected device/foreign body. [16][24]

### Role of intravenous immunoglobulin

CDC states that IVIG can be considered early for severely ill patients with STSS, but efficacy has not been proven. [16] A pediatric review found variable outcomes with IVIG and no significant difference in measured outcomes among treatment groups in its retrospective cohort. [18] Use should therefore be individualized, generally as an adjunct in severe or refractory toxin-mediated illness after immediate resuscitation, antimicrobials, and source-control planning are underway. [16][18]
- Document the rationale for IVIG as adjunctive, off-label use in this setting; the supplied sources do not establish an optimal dose. [16][18]
- Do not delay surgery, vasopressors, or appropriate antimicrobials while arranging IVIG. [16][24]

*Immediate management priorities for suspected TSS. [16][24]*

| Priority | Action | Practical endpoint |
| --- | --- | --- |
| Shock | Initiate intravenous fluid resuscitation and treat shock/organ failure in hospital; use vasopressors for fluid-refractory shock. [16][24] | Stabilizing perfusion and ongoing reassessment for multiorgan failure. [16][24] |
| Microbiology | Draw blood cultures and culture the suspected source when feasible without delaying treatment. [16][24] | Identify GAS, S. aureus, and susceptibility profile; narrow therapy when appropriate. [16][24] |
| Antimicrobials | Use broad empiric coverage when pathogen is unknown; use penicillin plus clindamycin for STSS. [16][24] | Early pathogen-directed therapy plus toxin-suppression strategy for GAS. [16][24] |
| Source control | Remove foreign material; drain abscesses; urgently debride deep or necrotizing infection. [16][24] | No retained nidus or devitalized infected tissue. [16][17] |
| Adjunctive therapy | Consider IVIG early in severely ill STSS, recognizing uncertain efficacy. [16] | Adjunct only; never replaces core resuscitative and source-control measures. [16] |

## Anticipate rapid deterioration and high morbidity

Deterioration can occur within hours, particularly in STSS with deep-tissue infection.

STSS can progress from influenza-like symptoms to hypotension within 24 to 48 hours. [16] Organ failure may involve renal, hepatic, respiratory, hematologic, and soft-tissue systems; complications include need for debridement or amputation. [16][20]

CDC reports that STSS mortality can exceed 30% despite aggressive treatment and is higher with advancing age. [16] In historical clinical descriptions, deep soft-tissue infection commonly required debridement, fasciotomy, or amputation. [17]

Monitor serial hemodynamics, vasopressor requirement, urine output and creatinine, platelets and coagulation studies, hepatic tests, oxygenation, CK when myositis is suspected, and repeated examination of the implicated soft-tissue compartment. [16][17][24]
- Escalate surgical reassessment for persistent pain, progressive edema/erythema, new bullae, rising CK, or worsening shock despite antimicrobial therapy. [17]
- Reassess microbiology daily and narrow therapy only after source control, cultures, and clinical trajectory support doing so. [16][24]
- For confirmed invasive GAS, CDC does not routinely recommend antibiotic prophylaxis or routine screening for household contacts; clinicians may consider prophylaxis when household members include persons at increased risk. [16]

*Monitoring domains in severe TSS. [16][17][24]*

| Domain | What to follow | Concerning trajectory |
| --- | --- | --- |
| Perfusion | Blood pressure, vasopressor requirement, mental status, urine output, renal function. [16][24] | Persistent or worsening shock, oliguria, or progressive kidney injury. [16][24] |
| Respiratory | Oxygenation and pulmonary status. [16][18] | New or worsening pulmonary infiltrates or respiratory failure. [16][18] |
| Hematologic/hepatic | Platelets, coagulation studies, bilirubin, aminotransferases. [16][24] | Progressive thrombocytopenia, coagulopathy, or hepatic dysfunction. [16][24] |
| Soft tissue | Pain, swelling, erythema, bullae, compartment findings, CK when clinically indicated. [17][24] | Rapid local progression or evidence of necrosis requiring operative source control. [16][17] |

## Common questions

### Can toxic shock syndrome be diagnosed without rash?

Yes. Rash may be absent early and was absent in 48% of pediatric STSS cases in one series. Absence of rash must not delay resuscitation, cultures, source evaluation, antitoxin-active therapy, or surgical consultation when the clinical syndrome suggests TSS. [18]

### What is the first-line antibiotic regimen for streptococcal toxic shock syndrome?

CDC identifies penicillin plus clindamycin as first-line therapy for STSS. Use clindamycin in combination rather than alone, and pair antibiotics with immediate resuscitation and source control. The supplied sources do not provide dosing; follow current institutional severe invasive GAS protocols. [16][24]

### When should surgery be involved?

Immediately when deep soft-tissue infection is possible, especially with severe disproportionate pain, rapidly progressive swelling or erythema, vesicles, bullae, violaceous change, or refractory shock. Debridement may be necessary for STSS and should not await definitive imaging or late cutaneous findings. [16][17]

### Should IVIG be routinely given for STSS?

No. CDC permits consideration of IVIG early in severely ill STSS, but states that efficacy has not been proven. It should be individualized as adjunctive therapy after core resuscitation, antimicrobial therapy, and source-control planning are underway. [16][18]

## References
1. highlights of prescribing information — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8d2906e3-d059-425d-b971-29423963c2af&type=display
2. Colchicine Tablets USP, 0.6 mg
 
      
These highlights do not include all the information needed to use colchicine safely and effectively. See full prescribing information for COLCHICINE TABLETS.
 
      
COLCHICINE tablets, USP for oral use
 
      
Initial U.S. Approval: 1961 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f818ffe0-43df-4cc6-bc86-00b2c79b06fc&type=display
3. These highlights do not include all the information needed to use colchicine safely and effectively. See full prescribing information for Colchicine Tablets, USP. 
      Colchicine Tablets, USP, for oral use Initial U.S. Approval: 1961 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc439ae8-a79e-4942-8d02-22422b19b015&type=display
4. These highlights do not include all the information needed to use ZOSYN safely and effectively. See full prescribing information for ZOSYN.
      
         ZOSYN® (piperacillin and tazobactam) injection, for intravenous use
      Initial U.S. Approval: 1993 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ab9d90d-2f7f-4599-a44f-3d0a8f8ab623&type=display
5. Toxic Shock Syndrome Surveillance in the United States ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-96-6-875
6. Volume 11 Issue Supplement_1 | Clinical Infectious Diseases — academic.oup.com — https://academic.oup.com/cid/issue/11/Supplement_1
7. Epidemiology of Toxic Shock Syndrome in the United States — academic.oup.com — https://academic.oup.com/cid/article/11/Supplement_1/S14/306362
8. Tri-State Toxic-Shock Syndrome Study. II. Clinical and ... — academic.oup.com — https://academic.oup.com/jid/article-abstract/145/4/441/862034
9. Recurrent Nonmenstrual Toxic Shock Syndrome — academic.oup.com — https://academic.oup.com/cid/article-abstract/32/10/1470/466771
10. Toxic Shock Syndrome Toxin 1 - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/toxic-shock-syndrome-toxin-1
11. Lesson of the month 2: Toxic shock syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1470211824027854
12. Prognostic factors in patients hospitalised with group A ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0001706X25002153
13. Toxic Shock Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/toxic-shock-syndrome
14. Group A Streptococcal Pharyngitis — www.idsociety.org — https://www.idsociety.org/practice-guideline/streptococcal-pharyngitis2
15. Early and Definitive Diagnosis of Toxic Shock Syndrome by Detection of Marked Expansion of T-Cell-Receptor Vβ2-Positive T Cells - Volume 9, Number 3—March 2003 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/9/3/02-0360_article
16. Clinical Guidance for Streptococcal Toxic Shock Syndrome | Group A Strep | CDC — www.cdc.gov — https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/streptococcal-toxic-shock-syndrome.html
17. Streptococcal Toxic-Shock Syndrome — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/1/3/pdfs/95-0301.pdf
18. Manifestations of Toxic Shock Syndrome in Children, Columbus, Ohio, USA, 2010–2017 - Volume 26, Number 6—June 2020 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/26/6/19-0783_article
19. Superantigens and Streptococcal Toxic Shock Syndrome - Volume 9, Number 10—October 2003 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/9/10/03-0042_article
20. About Streptococcal Toxic Shock Syndrome | Group A Strep | CDC — www.cdc.gov — https://www.cdc.gov/group-a-strep/about/streptococcal-toxic-shock-syndrome.html
21. Toxic Shock Syndrome in Patients Younger than 21 Years ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/114464/cdc_114464_DS1.pdf
22. Staphylococcal Toxic Shock Syndrome 2000–2006 — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/22808/cdc_22808_DS1.pdf
23. The Management of Staphylococcal Toxic Shock Syndrome. A Case Report - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5939132
24. Toxic Shock Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459345

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.